ArticleScientific reports2016
Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis.PloS one · 2026Trial
- Microfluidic diffusional sizing in bioanalysis and biosensing.Lab on a chip · 2026Review
- Novel Macrocyclic Compounds Targeting STING for Autoimmune Diseases Treatment.ACS medicinal chemistry letters · 2026Article
- Development of Bispecific Antibody Targeting Human IL-17A and IL-6.Antibodies (Basel, Switzerland) · 2026Article
- Recombinant LAB vector engineered to secrete chicken IFN-λ3 induces an early but sustained activation of antiviral host responses against AIV infection.Poultry science · 2025Article
- The Therapeutic Potential ofInternational journal of molecular sciences · 2025Article
- Advances in sulfonyl exchange chemical biology: expanding druggable target space.Chemical science · 2025Review
- Article
- Modulation of IL-17 backbone dynamics reduces receptor affinity and reveals a new inhibitory mechanism.Chemical science · 2023Article
- Identification of small-molecule protein-protein interaction inhibitors for NKG2D.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Sulfur(VI) fluorides as tools in biomolecular and medicinal chemistry.Organic & biomolecular chemistry · 2023Review
- It's ok to be outnumbered - sub-stoichiometric modulation of homomeric protein complexes.RSC medicinal chemistry · 2023Review
- Covalent drugs targeting histidine - an unexploited opportunity?RSC medicinal chemistry · 2022Article
- Multicomponent Macrocyclic IL-17a Modifier.ACS medicinal chemistry letters · 2022Article
- Identification and structure-based drug design of cell-active inhibitors of interleukin 17A at a novel C-terminal site.Scientific reports · 2022Article
- Protein-protein interaction and in silico mutagenesis studies on IL17A and its peptide inhibitor.3 Biotech · 2021Article
- Structure-based design and analysis of SuFEx chemical probes.RSC medicinal chemistry · 2020Review
- Utilization of peptide phage display to investigate hotspots on IL-17A and what it means for drug discovery.PloS one · 2018Article
- Artificial Macrocycles as IL-17A/IL-17RA Antagonists.MedChemComm · 2018Article
- The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor recognition properties.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-17A (IL-17A) is a principal driver of multiple inflammatory and immune disorders. Antibodies that neutralize IL-17A or its receptor (IL-17RA) deliver efficacy in autoimmune diseases, but no small-molecule IL-17A antagonists have yet progressed into clinical trials. Investigation of a series of linear peptide ligands to IL-17A and characterization of their binding site has enabled the design of novel macrocyclic ligands that are themselves potent IL-17A antagonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.